Get the Stockscreener App
0.7175
6.53%
-0.0501
After Hours:
.71
-0.0075
-1.05%
Cue Biopharma Inc stock is traded at $0.7175, with a volume of 137.33K.
It is down -6.53% in the last 24 hours and down -1.59% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.7676
Open:
$0.74
24h Volume:
137.33K
Relative Volume:
0.75
Market Cap:
$55.14M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.7885
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-6.87%
1M Performance:
-1.59%
6M Performance:
-4.66%
1Y Performance:
-52.80%
1-Day Range:
$0.7008
$0.767
1-Week Range:
$0.6801
$0.7766
52-Week Range:
$0.5406
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.7175 | 58.99M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
How Cue Biopharma Inc. stock reacts to global recession fearsFed Meeting & Real-Time Sentiment Analysis - newser.com
Risk adjusted return profile for Cue Biopharma Inc. analyzedJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Can trapped investors hope for a rebound in Cue Biopharma Inc. - newser.com
How Cue Biopharma Inc. stock performs in rate cut cycles2025 Analyst Calls & AI Enhanced Trade Execution Alerts - newser.com
What dividend safety score for Cue Biopharma Inc. stockMarket Growth Report & Community Trade Idea Sharing - newser.com
Full technical analysis of Cue Biopharma Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Is Cue Biopharma Inc. reversing from oversold territoryJuly 2025 Highlights & Free Long-Term Investment Growth Plans - newser.com
Historical volatility pattern of Cue Biopharma Inc. visualizedPortfolio Risk Report & Weekly Chart Analysis and Guides - newser.com
Trend analysis for Cue Biopharma Inc. this weekJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
Is Cue Biopharma Inc. stock vulnerable to regulatory risksDip Buying & Fast Momentum Stock Entry Tips - newser.com
How Cue Biopharma Inc. (1UC) stock stacks up against competitorsRate Hike & Free Community Supported Trade Ideas - newser.com
Live market analysis of Cue Biopharma Inc.2025 Year in Review & Fast Entry High Yield Stock Tips - newser.com
Using Ichimoku Cloud for Cue Biopharma Inc. technicalsJuly 2025 Big Picture & AI Optimized Trade Strategies - newser.com
Why Cue Biopharma Inc. (1UC) stock could be next leaderLong Setup & Weekly Top Gainers Alerts - newser.com
Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Declines By 44.6% - MarketBeat
Cue Biopharma Inc. recovery potential after sell offQuarterly Profit Summary & High Accuracy Swing Trade Signals - newser.com
Is Cue Biopharma Inc. stock gaining market shareIPO Watch & Risk Managed Investment Strategies - newser.com
Is Cue Biopharma Inc. stock in correction or buying zoneWeekly Profit Summary & Weekly Top Performers Watchlists - newser.com
What is the fair value of Cue Biopharma Inc. stock nowPortfolio Value Summary & High Conviction Investment Ideas - newser.com
Is Cue Biopharma Inc. (1UC) stock undervalued after correctionWeekly Market Outlook & Target Return Focused Stock Picks - newser.com
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):